AzTrials
AzTrials

West Nile VirusNCT05294003

West Nile Virus Seroprevalence Under Bird Ringers

An observational study of West Nile Virus, run by Leiden University Medical Center at 1 site in Netherlands.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

In August 2020, West Nile Virus (WNV) was isolated from a live common whitethroat for the first time in The Netherlands. Follow-up sampling showed that the virus could also be detected in mosquitos from the same location during at least a whole month of sampling. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
West Nile Virus
How many people
162 participants
Where
1 siteNetherlands
Study dates
28 May 2021to 14 Dec 2021
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Bird ringers from the Netherlands (about 580 licensed ringers and about 100 additional trainees or helpers)

Who may be able to join

  • Carrying-out bird ringing activities during spring, summer or early autumn 2020 in The Netherlands

Who cannot join

  • Not willing to participate in this study
  • Using medication interfering with antibodies production
  • Under 18 years of age

Trial locations and contacts

1 site in 1 country.

Netherlands1 site
  • Leiden University Medical Centre (LUMC)

    Leiden

Other trials in Netherlands

About this study

Official title: Prevalence of West Nile Virus and Usutu Virus Serum Antibodies in Dutch Bird Ringers

In August 2020, West Nile Virus (WNV) was isolated from a live common whitethroat for the first time in The Netherlands. Follow-up sampling showed that the virus could also be detected in mosquitos from the same location during at least a whole month of sampling. On 15 October 2020, one case of West Nile virus infection has been reported in a man who was likely infected in the Utrecht region. This is the first time that a locally acquired human case of WNV infection has been reported in The Netherlands. Six additional cases have been identified, one of which from the region Arnhem. West Nile virus infection is a mosquito-borne zoonosis. The disease, which has spread across the Northern Hemisphere in the past three decades, is now found on an annual basis in many European countries where the centre of gravity lies in Southern-European countries. Recently, WNV was reported for the first time in Germany. The virus is transmitted among birds through the bite of infected mosquitoes and incidentally infects humans and other mammals, such as horses. Around 80% of human WNV infections are asymptomatic. The most common clinical presentation is West Nile fever but, older people and immunocompromised persons are at higher risk of developing neuro-invasive disorders (West Nile neuroinvasive disease). Currently, there are no prophylaxis or specific treatment against the disease in humans. In addition, Usutu virus (USUV) was detected in The Netherlands in 2016. USUV is another flavivirus, related to WNV, and also capable of infecting humans. Disease associated with USUV infection in humans appears to be milder and only limited number of cases have been identified. During their bird catching activities, bird ringers are intensively exposed to mosquito bites at the natural habitat of the birds and at the same time of the day when mosquitoes are particularly active. The aim of this study is therefore to determine the prevalence of WNV and USUV serum antibodies in bird ringers in The Netherlands.

Conditions
West Nile Virus

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The proportion of individuals with neutralising antibodies against WNV by region

    Measured: One blood sample collected between June and September 2021

  2. The proportion of individuals with neutralising antibodies against USUV by region

    Measured: One blood sample collected between June and September 2021

Secondary outcomes (4)
  1. The proportion of individuals with IgM antibodies against WNV

    Measured: One blood sample collected between June and September 2021

  2. The proportion of individuals with IgG antibodies against WNV

    Measured: One blood sample collected between June and September 2021

  3. The proportion of individuals with IgM antibodies against USUV

    Measured: One blood sample collected between June and September 2021

  4. The proportion of individuals with IgG antibodies against USUV

    Measured: One blood sample collected between June and September 2021

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Mar 2022
  2. Study start28 May 2021
  3. Primary completion22 Sep 2021
  4. Study completion14 Dec 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
162 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05294003
Sponsor's protocol ID
P20.112
Status last verified
Mar 2022
First submitted
15 Feb 2022
Last updated
24 Mar 2022
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Sikkema RS, Schrama M, van den Berg T, Morren J, Munger E, Krol L, van der Beek JG, Blom R, Chestakova I, van der Linden A, Boter M, van Mastrigt T, Molenkamp R, Koenraadt CJ, van den Brand JM, Oude Munnink BB, Koopmans MP, van der Jeugd H. Detection of West Nile virus in a common whitethroat (Curruca communis) and Culex mosquitoes in the Netherlands, 2020. Euro Surveill. 2020 Oct;25(40):2001704. doi: 10.2807/1560-7917.ES.2020.25.40.2001704.

    PubMed 33034280
  • Ziegler U, Santos PD, Groschup MH, Hattendorf C, Eiden M, Hoper D, Eisermann P, Keller M, Michel F, Klopfleisch R, Muller K, Werner D, Kampen H, Beer M, Frank C, Lachmann R, Tews BA, Wylezich C, Rinder M, Lachmann L, Grunewald T, Szentiks CA, Sieg M, Schmidt-Chanasit J, Cadar D, Luhken R. West Nile Virus Epidemic in Germany Triggered by Epizootic Emergence, 2019. Viruses. 2020 Apr 15;12(4):448. doi: 10.3390/v12040448.

    PubMed 32326472
  • Gaibani P, Rossini G. An overview of Usutu virus. Microbes Infect. 2017 Jul-Aug;19(7-8):382-387. doi: 10.1016/j.micinf.2017.05.003. Epub 2017 Jun 8.

    PubMed 28602915
  • Rijks JM, Kik ML, Slaterus R, Foppen R, Stroo A, IJzer J, Stahl J, Grone A, Koopmans M, van der Jeugd HP, Reusken C. Widespread Usutu virus outbreak in birds in the Netherlands, 2016. Euro Surveill. 2016 Nov 10;21(45):30391. doi: 10.2807/1560-7917.ES.2016.21.45.30391.

    PubMed 27918257
  • Oude Munnink BB, Munger E, Nieuwenhuijse DF, Kohl R, van der Linden A, Schapendonk CME, van der Jeugd H, Kik M, Rijks JM, Reusken CBEM, Koopmans M. Genomic monitoring to understand the emergence and spread of Usutu virus in the Netherlands, 2016-2018. Sci Rep. 2020 Feb 18;10(1):2798. doi: 10.1038/s41598-020-59692-y.

    PubMed 32071379

Questions about this trial

What is this clinical trial studying?

An observational study of West Nile Virus, run by Leiden University Medical Center at 1 site in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 24 Mar 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The proportion of individuals with neutralising antibodies against WNV by region (time frame: One blood sample collected between June and September 2021). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05294003, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Mar 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in